Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational drug combination consists of the intermediate-acting non-depolarizing neuromuscular blocking agent atracurium besylate added to a local anesthetic mixture of lidocaine, bupivacaine, and hyaluronidase. It was evaluated by researchers at Kasr El Aini Hospital for use in percaruncular peribulbar anesthesia during cataract surgery, specifically in patients with high myopia. Atracurium serves as an adjuvant to achieve rapid and complete akinesia of the extraocular muscles by competitively antagonizing nicotinic acetylcholine receptors at the neuromuscular junction. The local anesthetics lidocaine and bupivacaine provide regional anesthesia by blocking voltage-gated sodium channels, while hyaluronidase facilitates the dispersion of the mixture through the orbital tissues by degrading hyaluronan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atracurium + lidocaine + bupivacaine + hyaluronidase.